false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Onconep ...
What's New? Immune Checkpoint Inhibitors: Biomarke ...
What's New? Immune Checkpoint Inhibitors: Biomarkers, Imaging, and Rechallenge
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Shruti Gupta discusses diagnosing immune checkpoint inhibitor–associated acute kidney injury (ICI-AKI), especially acute interstitial nephritis, and deciding whether to restart immunotherapy. Because creatinine and routine urine findings cannot reliably distinguish ICI-AKI from other causes, kidney biopsy is often important when feasible, particularly when alternative causes are possible.<br /><br />Emerging biomarkers—including urinary CXCL9, TNF-alpha, and cell-free RNA, as well as serum soluble IL-2 receptor—show promise but need larger external validation. Early research also suggests increased kidney uptake on PET scans may help identify ICI-AKI.<br /><br />Most patients recover kidney function, and early corticosteroid treatment is associated with better recovery. In cohort studies, fewer than one in five rechallenged patients developed recurrent ICI-AKI, challenging guidelines that recommend permanent discontinuation after severe injury. Rechallenge decisions should balance kidney recovery and injury severity with cancer response, treatment alternatives, and urgency. Gupta emphasizes the need for prospective studies and better tools to guide diagnosis, treatment, and rechallenge.
Asset Caption
Shruti Gupta, MD, MPH
Meta Tag
Speaker
Shruti Gupta
Keywords
immune checkpoint inhibitor
acute kidney injury
acute interstitial nephritis
kidney biopsy
biomarkers
immunotherapy rechallenge
×
Please select your language
1
English